Literature DB >> 22870096

Surgical management of metastatic adrenal tumors: Decision-making factors in imaging.

Sunao Shoji1, Yukio Usui, Mayura Nakano, Kazuya Hanai, Haruhiro Sato, Toyoaki Uchida, Toshiro Terachi.   

Abstract

The present study aimed to clarify decision-making factors based on imaging for laparoscopic adrenalectomy (LA) or open adrenalectomy (OA) for adrenal metastasis (AM) based on our previous experience. From November 2003 to November 2006, 11 adrenalectomies were performed for AM for malignancies such as lung cancer, renal cell carcinoma (RCC) and breast cancer at Tokai University Hospital. A diagnosis of AM for these malignancies was suspected whenever a newly diagnosed adrenal mass was located, characterized by a basal computed tomography (CT) density superior to 10 Hounsfield units, strong or heterogeneous vascular enhancement following contrast injection and/or increasing size in sequential imaging studies. There was no evidence of extra-AM. The approach to surgical management using LA or OA was determined on the basis of CT and/or magnetic resonance imaging. The patients were reviewed every 2 or 3 months by physical examination and systemic CT. We analyzed the decision-making factors based on imaging for surgical management with LA or OA from the results of oncological outcome, imaging, intraoperative and pathohistological findings. In this study, 9 patients underwent 11 adrenalectomies (9 laparoscopic and 2 open procedures). Non-small cell lung cancer was the most common primary malignancy (5 adrenalectomies of 4 patients), followed by RCC (4 adrenalectomies of 4 patients) and breast cancer (2 adrenalectomies of 1 patient). The median tumor size for the LA group was 3.1±0.7 cm (range 2.1-4.3) and for the OA group, 6.1±0.8 cm (5.5 and 6.7 cm) (p=0.001). The operative time for the LA group was 127±42 min (range 90-215) and for the OA group, 224±47 min (190 and 257 min) (p=0.018). Blood loss for the LA group was 49±63 g (range 3-207) and for the OA group, 340±10 g (333 and 347 g) (p<0.001). No complications were noted and no conversion of LA to OA occurred. All 9 adrenal tumors selected for LA were removed safely without strong adhesion to the surrounding tissue. Two adrenal tumors removed by OA had a strong adhesion to the surrounding tissue. All 9 patients had complete resection, without capsular disruption and a negative margin in the pathological findings. No port-site and local recurrences occurred. No patients presented with local relapse or port-site metastasis. Disease-free survival rate for the LA group was 57% and for the OA group, 50% (p=0.661). LA is a less invasive treatment than OA for AM. However, for complete resection, OA should be selected for cases where resection by LA is difficult. Therefore, in the decision making towards the appropriate surgical management with LA or OA, it is important to closely assess pre-operative imaging. Imaging features supporting OA include no detection of fatty tissue between the tumor and proximal organs, tumors with an irregular contour, large tumors and tumors with a cystic component.

Entities:  

Year:  2010        PMID: 22870096      PMCID: PMC3412471          DOI: 10.3892/ol.2010.183

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  10 in total

1.  Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma.

Authors:  M Gagner; A Lacroix; E Bolté
Journal:  N Engl J Med       Date:  1992-10-01       Impact factor: 91.245

2.  A case of port-site recurrence after laparoscopic adrenalectomy for solitary adrenal metastasis.

Authors:  Dirk Weyhe; Orlin Belyaev; Sebastian Skawran; Christophe Müller; Karl-Heinz Bauer
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2007-06       Impact factor: 1.719

Review 3.  Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management.

Authors:  T Liakakos; N Thomakos; P M Fine; C Dervenis; R L Young
Journal:  Dig Surg       Date:  2001       Impact factor: 2.588

4.  Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery.

Authors:  Kazushi Tanaka; Isao Hara; Atsushi Takenaka; Gaku Kawabata; Masato Fujisawa
Journal:  Urology       Date:  2008-02-15       Impact factor: 2.649

5.  Successful treatment of adrenal metastases from large-cell carcinoma of the lung.

Authors:  P Twomey; C Montgomery; O Clark
Journal:  JAMA       Date:  1982-08-06       Impact factor: 56.272

6.  Isolated adrenal metastasis: the role of laparoscopic surgery.

Authors:  F Sebag; F Calzolari; J Harding; M Sierra; F F Palazzo; J F Henry
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

7.  Laparoscopic adrenalectomy for isolated adrenal metastasis.

Authors:  Vivian E Strong; Michael D'Angelica; Laura Tang; Francesco Prete; Mithat Gönen; Daniel Coit; Karim A Touijer; Yuman Fong; Murray F Brennan
Journal:  Ann Surg Oncol       Date:  2007-07-31       Impact factor: 5.344

8.  Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.

Authors:  Scott E Eggener; Ofer Yossepowitch; Shilajit Kundu; Robert J Motzer; Paul Russo
Journal:  J Urol       Date:  2008-07-17       Impact factor: 7.450

Review 9.  Laparoscopic adrenalectomy for adrenal carcinoma and metastases.

Authors:  Hiroyoshi Suzuki
Journal:  Curr Opin Urol       Date:  2006-03       Impact factor: 2.309

10.  Solitary adrenal metastasis from invasive ductal breast cancer: an uncommon finding.

Authors:  Xiao-Jiao Liu; Peng Shen; Xin-Feng Wang; Ke Sun; Fei-Fei Sun
Journal:  World J Surg Oncol       Date:  2010-01-28       Impact factor: 2.754

  10 in total
  2 in total

1.  Adrenal Gland Metastasis of Breast Invasive Mucinous Carcinoma: A Rare Case Report and Review of Literature.

Authors:  Dingqi Sun; Jinhua Wang; Keqin Zhang; Hui Zhang; Tongxiang Diao; Qiang Fu
Journal:  Case Rep Oncol       Date:  2022-06-23

2.  Left adrenal gland metastasis of breast invasive ductal carcinoma: A case report.

Authors:  Tao He; Jiaju Liu; Yifan Li; L U Jin; Shuolei Sun; Liangchao Ni; Xiangming Mao; Shangqi Yang; Yongqing Lai
Journal:  Mol Clin Oncol       Date:  2016-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.